Taiwan’s US Representative Yui Tours PharmaEssentia Plant with Puerto Rico Officials

On April 20, 2023, Taiwan’s Representative to the United States, Alexander Tah-ray Yui, visited PharmaEssentia’s facility in Puerto Rico. This visit included key officials from both Taiwan and Puerto Rico, emphasizing their collaboration in U.S. manufacturing efforts.
Significant Visit Highlights
Yui was accompanied by Mme. Karen Lo, Charles Chi Yu Chou, and Felipe Tsai. Their presence marked another step in strengthening Taiwan’s international biotech footprint.
Government Officials Involved
- Alexander Tah-ray Yui – Taiwan’s U.S. Representative
- Mme. Karen Lo – Taiwan Official
- Charles Chi Yu Chou – Director General, TECO Miami
- Felipe Tsai – Deputy Director, TECO Miami
- Bernardo Márquez – Mayor of Toa Baja, Puerto Rico
- James Ramos – Economic Development Director, Toa Baja
- Soraya Morón – Deputy Secretary, DDEC
- Denisse Rodriguez – Stakeholder Affairs Director, Invest Puerto Rico
Focus on the Dual Taiwan-U.S. Production Base Strategy
The delegation toured PharmaEssentia’s facility, seeing firsthand its construction progress. This facility is critical for expanding local production as part of the company’s “Dual Taiwan-U.S. Production Base” strategy, aimed at building a resilient supply chain.
PharmaEssentia’s Commitment
PharmaEssentia, headquartered in Taipei, Taiwan, is a growing player in the biopharmaceutical sector. The company is dedicated to advancing research and development, and enhancing its global operations, including this new facility in Puerto Rico designed to support its long-term growth.
Future Prospects
This visit solidified the commitment of both Taiwan and Puerto Rico to foster cooperation in the biotechnology field. PharmaEssentia aims to leverage innovative research alongside international manufacturing to enhance its presence in the global market.
As PharmaEssentia progresses in operational development, it maintains a proactive stance in engaging with both local and international stakeholders, reflecting its aspirations for growth and success in the biopharmaceutical landscape.



